BTK and myeloid sarcoma: The novel, highly selective, central nervous system-penetrating, irreversible BTK inhibitor evobrutinib strongly suppresses BCR- and Fc receptor-mediated signaling, which makes it a promising agent in the treatment of RA, MS, and other autoimmune diseases [19,134,135] (Table 2).